{
    "nctId": "NCT03749421",
    "briefTitle": "Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer",
    "officialTitle": "Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "The extent to which the Prosigna test results will change physician's pre-test decision regarding neoadjuvant treatment of patients with stage II-III ER/PR+, HER2-negative breast cancer",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients pre- or post-menopausal must have histologically confirmed early stage/locally advanced invasive breast cancer\n* ER or PR \u2265 1% by immunohistochemistry (IHC)\n* HER2-negative status, according to guidelines by ASCO CAP guidelines:\n\nhttps://www.asco.org/practice-guidelines/quality-guidelines/guidelines/breast-cancer#/9751\n\n* Tumor size \u2265 0.5cm (clinical or radiographic measurements)\n* Any nodal status allowed\n* Age \\> 18 years old\n* Felt to be a possible candidate for neoadjuvant systemic therapy by their treating physician\n\nExclusion Criteria:\n\n* ER-negative and PR-negative invasive breast cancer (\\< 1% by IHC)\n* Known metastatic disease",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}